Microbot Medical Inc. (NasdaqCM:MBOT) will look for acquisitions. Microbot Medical Inc. has entered into definitive agreements with several institutional investors for the purchase of 590,000 shares of its common stock, at a purchase price per share of $10, in a registered direct offering priced at-the-market, to raise gross proceeds of $5.9 million. Microbot Medical intends to use the proceeds for the continuous development of its SCS device for the treatment of hydrocephalus and NPH, to expand and develop additional applications deriving from its existing IP portfolio, including the potential addition of complementary assets to the CardioSert portfolio either through internal development, in-license or acquisition, and for working capital and other general corporate purposes.